首页> 外文期刊>Journal of ocular pharmacology and therapeutics: The official journal of the Association for Ocular Pharmacology and Therapeutics >Bioactive lysophospholipids: Role in regulation of aqueous humor outflow and intraocular pressure in the context of pathobiology and therapy of glaucoma
【24h】

Bioactive lysophospholipids: Role in regulation of aqueous humor outflow and intraocular pressure in the context of pathobiology and therapy of glaucoma

机译:具有生物活性的溶血磷脂:在青光眼的病理生物学和治疗中调节房水流出和眼内压的作用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Homeostasis of aqueous humor (AH) outflow and intraocular pressure (IOP) is essential for normal vision. Impaired AH outflow through the trabecular meshwork (TM) and a resultant elevation in IOP are common changes in primary open-angle glaucoma (POAG), which is the most prevalent form of glaucoma. Although elevated IOP has been recognized as a definitive risk factor for POAG and lowering elevated IOP remains a mainstay for glaucoma treatment, little is known about the molecular mechanisms, especially external cues and intracellular pathways, involved in the regulation of AH outflow in both normal and glaucomatous eyes. In addition, despite the recognition that increased resistance to AH outflow via the conventional pathway consisting of TM and Schlemm's canal is the main cause for elevated IOP, there are no clinically approved drugs that target the conventional pathway to lower IOP in glaucoma patients. The aim of this article is to briefly review published work on the importance of bioactive lysophospholipids (eg, lysophosphatidic acid and sphingosine-1-phosphate), their receptors, metabolism, signaling, and role in the regulation of AH outflow via the TM and IOP, and to discuss pharmacological targeting of key proteins in the lysophospholipid signaling pathways to lower IOP in glaucoma patients.
机译:房水(AH)流出和眼内压(IOP)的稳态对于正常视力至关重要。通过小梁网(TM)引起的AH流出受损以及由此引起的IOP升高是原发性开角型青光眼(POAG)的常见变化,这是青光眼最普遍的形式。尽管IOP升高是公认的POAG危险因素,降低IOP仍是青光眼治疗的主要手段,但对于正常和正常人AH流出调节的分子机制,尤其是外部提示和细胞内途径了解甚少。青光眼的眼睛。此外,尽管认识到通过常规途径(包括TM和Schlemm根管)对AH流出的抵抗力增加是导致IOP升高的主要原因,但目前尚无临床认可的药物靶向传统途径以降低青光眼患者的IOP。本文的目的是简要回顾已发表的有关生物活性溶血磷脂(例如,溶血磷脂酸和鞘氨醇-1-磷酸),其受体,代谢,信号传导以及在通过TM和IOP调节AH流出的作用中的重要性的工作,并讨论溶血磷脂信号通路中关键蛋白的药理靶向作用,以降低青光眼患者的IOP。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号